Out Patient Talc Slurry Via Indwelling Pleural Catheter for Malignant Pleural Effusion Vs Usual Inpatient Management (OPTIMUM)
Randomised Controlled Trial Comparing Outpatient Management of Malignant Pleural Effusion Via an Indwelling Pleural Catheter and Talc Pleurodesis Versus Standard Inpatient Management in Improving Health Related Quality of Life
Sponsor: Becton, Dickinson and Company
Listed as NCT02517749, this NA trial focuses on Pleural Effusion, Malignant and remains completed. Sponsored by Becton, Dickinson and Company, it has been updated 10 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Dec 2023 — Jul 2024 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Mar 2022 — Dec 2023 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting NA
▶ Show 5 earlier versions
-
Jan 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Jan 2020 [monthly]
Recruiting NA
-
Jun 2018 — Sep 2018 [monthly]
Recruiting NA
-
Feb 2017 — Jun 2018 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Aug 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Becton, Dickinson and Company
- Guy's and St Thomas' NHS Foundation Trust
For direct contact, visit the study record on ClinicalTrials.gov .